COMMUNIQUÉS West-GlobeNewswire
-
CorMedix Inc. Announces New Commercial Agreement
09/09/2024 - 16:52 -
World-renowned diabetes researcher joins Wendy Novak Diabetes Institute
09/09/2024 - 16:30 -
PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian
09/09/2024 - 16:22 -
Novo Nordisk A/S - share repurchase programme
09/09/2024 - 16:10 -
ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan
09/09/2024 - 16:01 -
Novo Nordisk A/S - share repurchase programme
09/09/2024 - 15:55 -
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
09/09/2024 - 15:31 -
Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference
09/09/2024 - 15:00 -
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
09/09/2024 - 15:00 -
Stereotaxis to Present at Upcoming Investor Conferences
09/09/2024 - 14:40 -
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
09/09/2024 - 14:30 -
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
09/09/2024 - 14:30 -
Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
09/09/2024 - 14:30 -
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
09/09/2024 - 14:30 -
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
09/09/2024 - 14:30 -
September 2024 Letter to Shareholders
09/09/2024 - 14:30 -
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
09/09/2024 - 14:30 -
Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year
09/09/2024 - 14:30 -
Cassava Sciences Names Rick Barry as Chief Executive Officer
09/09/2024 - 14:30
Pages